Skip to main content
PTN
NASDAQ Life Sciences

Shareholders to Vote on 14.6% Potential Dilution for Equity Incentive Plan

Analysis by Wiseek AI
Sentiment info
Neutral
Importance info
7
Price
$10.25
Mkt Cap
$18.238M
52W Low
$5
52W High
$31
Market data snapshot near publication time

Summary

Palatin Technologies has filed a definitive proxy statement for its annual meeting, where shareholders will vote on a proposal to add 260,000 shares to the equity incentive plan, representing a significant potential dilution of 14.6% of current outstanding shares.


Key Events

  • Annual Shareholder Meeting Scheduled

    The Annual Meeting of Stockholders will be held virtually on Tuesday, July 28, 2026, at 9:00 a.m. Eastern Time.

  • Proposed Equity Plan Expansion

    Shareholders will vote on an amendment to the 2011 Stock Incentive Plan to increase the number of shares reserved for issuance by 260,000 shares.

  • Significant Potential Dilution

    The additional 260,000 shares represent a potential dilution of approximately 14.6% based on the 1,779,275 common shares outstanding as of June 22, 2026. The total fully diluted overhang from the plan would increase from 6.6% to 17.8% if approved.

  • Advisory Vote on Executive Compensation

    Shareholders will cast a non-binding, advisory vote on the compensation of the named executive officers for the fiscal year ended June 30, 2025.


Analysis

Palatin Technologies is seeking shareholder approval to increase the shares reserved for its 2011 Stock Incentive Plan by 260,000 shares. This represents a potential dilution of approximately 14.6% relative to the current outstanding common stock. While necessary for employee incentives, this is a substantial increase in potential future dilution for a company with a market capitalization of approximately $18.2 million. The company noted that without this increase, it might need to rely more on cash compensation, which could increase expenses and reduce alignment with shareholder interests.

At the time of this filing, PTN was trading at $10.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.2M. The 52-week trading range was $5.00 to $31.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PTN - Latest Insights

PTN
Jun 25, 2026, 4:15 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $10.25
Real-time Price: $10.25 info
Change: $0 (0%) info
Market Cap: $18.238M info